Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.Emilio Iannitto,Simone Ferrero,Côme Bommier,Daniela Drandi,Martina Ferrante,Krimo Bouabdallah,Sylvain Carras,Guido Gini,Vincent Camus,Salvatrice Mancuso,Luigi Marcheselli,Angela Ferrari,Michele Merli,Benoit Tessoulin,Caterina Stelitano, Kheira Beldjord,Giovanni Roti,Fabrice Jardin,Barbara Castagnari,Francesca Palombi,Lucile Baseggio,Alexandra Traverse-Glehen,Claudio Tripodo,Anna Marina Liberati, Margherita Parolini, Sara Usai,Caterina Patti,Massimo Federico,Maurizio Musso,Marco Ladetto,Emanuele Zucca,Catherine ThieblemontHaematologica(2024)引用 0|浏览13暂无评分摘要Not available.更多查看译文AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要